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Review Article
Graves’ disease was first recognized in the 19th century as a syndrome comprising an enlarged and overactive thyroid gland, an accel-erated heart rate, and ocular abnormalities (Fig. 1). Critical for our current 
understanding of this disease was the discovery of its autoimmune basis, which 
results from complex interactions between genetic and environmental factors.1,2 
Graves’ disease has adverse effects on quality of life,3 as a consequence of so-
matic4 and psychiatric5 symptoms and an inability to work,6 and is associated with 
an increased risk of death.7 Activating thyrotropin-receptor antibodies induce thyroid 
hormone overproduction. Many characteristic signs and symptoms of Graves’ dis-
ease result from elevated thyroid hormone levels. Debate persists concerning the 
diagnosis of hyperthyroidism and adequate clinical care of affected patients.8,9 
Thyroid-associated ophthalmopathy (Fig. 1B), the most common and serious ex-
trathyroidal manifestation, results from underlying autoimmunity, but insights 
into its pathogenesis and care remain elusive.
Epidemiol o gy
Graves’ disease is the most common cause of hyperthyroidism, with an annual 
incidence of 20 to 50 cases per 100,000 persons.10 The incidence peaks between 30 
and 50 years of age, but people can be affected at any age. The lifetime risk is 3% 
for women and 0.5% for men. Long-term variations in iodine intake do not influ-
ence the risk of disease, but rapid repletion can transiently increase the incidence. 
The annual incidence of Graves’ disease–associated ophthalmopathy is 16 cases 
per 100,000 women and 3 cases per 100,000 men. It is more common in whites 
than in Asians.11 Severe ophthalmopathy is more likely to develop in older men 
than in younger persons.12 Orbital imaging reveals subtle abnormalities in 70% of 
patients with Graves’ disease.13 In specialized centers, clinically consequential 
ophthalmopathy is detected in up to 50% of patients with Graves’ disease, and it 
threatens sight as a consequence of corneal breakdown or optic neuropathy in 3 to 
5% of such patients.14 Hyperthyroidism and ophthalmopathy typically occur within 
1 year of each other but can be separated by decades. In 10% of persons with 
ophthalmopathy, either thyroid levels remain normal or autoimmune hypothyroid-
ism develops.12,14
Clinic a l Pr esen tation
Hyperthyroidism
The manifestations of Graves’ disease depend on the age of the patient at the 
onset of hyperthyroidism, as well as the severity and the duration of hyperthyroid-
ism.15 Symptoms and signs result from hyperthyroidism (goiter in some cases) or 
are a consequence of underlying autoimmunity (Table 1). Weight loss, fatigue, heat 
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Gr aves’ Disease
intolerance, tremor, and palpitations are the most 
common symptoms, occurring in more than 50% 
of patients. Weight loss, decreased appetite, and 
cardiac manifestations are more common in elder-
ly persons with hyperthyroidism than in those 
who are younger. Atrial fibrillation due to hyper-
thyroidism is rare in patients who are younger 
than 60 years of age but occurs in more than 
10% of patients who are 60 years of age or older. 
Palpable goiter develops in most patients with 
hyperthyroidism who are younger than 60 years 
of age (Fig. 1A), as compared with less than 50% 
of older patients.16 Diffuse thyroid enlargement is 
most frequent, but many patients with Graves’ 
disease who live in iodine-deficient regions have 
coexisting nodular goiter.17
Figure 1. Clinical Manifestations of Graves’ Disease.
Panel A shows a diffuse, moderately enlarged goiter in a woman with Graves’ hyperthyroidism. Panel B shows moderate-
to-severe, thyroid-associated ophthalmopathy characterized by bilateral proptosis, periorbital edema, scleral injection, 
and lid retraction. Panel C shows the plaque form of pretibial dermopathy. Panel D shows acropachy with clubbing 
of the fingers.
A B
DC
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Thyroid-Associated Ophthalmopathy
Orbital involvement represents a parallel conse-
quence of the underlying autoimmunity occur-
ring within the thyroid. Ophthalmopathy can be 
disfiguring and can threaten sight. Its clinical 
course typically follows a pattern originally de-
scribed by Rundle and Wilson.18 Disease devel-
opment is heralded by an active phase lasting up 
to 3 years and dominated by evolving symptoms 
and signs of inflammation and congestion. Pro-
ptosis (Fig. 1B), eyelid swelling, and diplopia 
may prompt initial medical attention. Some pa-
tients have dry eye, increased tearing, and ocular 
discomfort early in the active phase. This is fol-
lowed by an inactive phase in which the ocular 
manifestations become stable. Table 1 lists the 
most common features of ophthalmopathy. In a 
cohort of consecutively assessed patients with 
Graves’ disease, the prevalence of distinct abnor-
malities was as follows: eyelid retraction, 92%; 
exophthalmos, 62%; extraocular muscle dysfunc-
tion, 43%; ocular pain, 30%; increased lacrima-
tion, 23%; and optic neuropathy, 6%.19
Mild eyelid retraction or lag may occur in 
thyrotoxicosis from any cause, as a result of in-
creased sympathetic tone. The activity of oph-
thalmopathy can be graded by assigning 1 point 
for each of the following manifestations: eyelid 
erythema and edema, conjunctiva injection, carun-
cular swelling, chemosis, retrobulbar pain, and 
pain with eye movement. A score of 3 or higher 
indicates active disease. The activity score — to-
gether with an evaluation of the severity of 
symptoms, including proptosis, reduced visual 
acuity, and impaired eye movement — guides 
treatment decisions.20
Localized Dermopathy and Acropachy
Thyroid dermopathy (Fig. 1C) occurs in 1 to 4% 
of patients with Graves’ disease and is nearly 
always seen in those with severe ophthalmopa-
thy.21 It most frequently localizes to the pretibial 
region but can occur elsewhere, especially after 
trauma to the skin. Acropachy resembles club-
bing of the fingers or toes and occurs only in 
patients with dermopathy 21 (Fig. 1D).
Patho genesis
Initiating Factors
Unambiguous identification of the factors un-
derlying Graves’ disease has not yet been accom-
plished. Genetic and epigenetic determinants are 
leading candidates for these factors.1,2,22 Large-
scale genetic analyses have identified several 
genes conferring susceptibility. These include 
genes encoding thyroglobulin, thyrotropin recep-
tor, HLA-DRβ-Arg74, the protein tyrosine phos-
phatase nonreceptor type 22 (PTPN22), cytotoxic 
Symptoms
Weight loss (weight gain in 10% of patients)
Palpitations
Dyspnea
Tremor
Tiredness, fatigue, muscle weakness
Heat intolerance, increased sweating
Increased stool frequency
Anxiety, altered mood, insomnia
Nervousness, hyperactivity
Pruritus
Thirst and polyuria
Menstrual disturbances in women (oligomenorrhea  
or amenorrhea)
Loss of libido
Neck fullness
Eye symptoms (swelling, pain, redness, double vision)
Physical signs of hyperthyroidism
Tachycardia, atrial fibrillation
Systolic hypertension, increased pulse pressure
Cardiac failure
Weight loss
Fine tremor, hyperkinesis, hyperreflexia
Warm, moist skin
Palmar erythema and onycholysis
Muscle weakness
Hair loss
Diffuse, palpable goiter and thyroid bruit
Mental-status and mood changes (e.g., mania  
or depression)
Extrathyroidal physical signs
Ophthalmopathy
Eyelid lag, retraction, or both
Proptosis (exophthalmos)
Double vision (extraocular-muscle dysfunction)
Periorbital edema, chemosis, scleral injection
Exposure keratitis
Optic neuropathy
Localized dermopathy
Acropachy
Table 1. Major Symptoms and Physical Signs in Graves’ 
Disease.
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T-lymphocyte–associated antigen 4 (CTLA4), 
CD25, and CD40.1 Hypermethylation of several 
genes has been identified, including those en-
coding thyrotropin receptor and proteins involved 
in T-cell signaling.22 Environmental factors such 
as dietary iodine, exposure to tobacco smoke, 
infections, and emotional stress are frequently 
cited. Therapy with alemtuzumab, a CD52-target-
ing monoclonal antibody, can induce Graves’ 
disease.23 How these diverse factors interact to 
confer a risk of disease remains uncertain.24
Anti–Thyrotropin-Receptor Antibodies
Activating autoantibodies of the IgG1 subclass 
that are directed against the thyrotropin recep-
tor are both specific for and central to Graves’ 
disease (Fig. 2A).25 Their oligoclonal generation, 
primarily by intrathyroidal B cells, reflects the 
disease’s primary autoimmune reaction. These 
antibodies stimulate thyroid hormone produc-
tion that is uncontrolled by the hypothalamic–
pituitary axis. Activating antibodies mimic the 
actions of thyrotropin at its receptor through the 
initiation of similar, but not identical, signaling.26 
In addition to activating antibodies, those that 
block the thyrotropin receptor can result in hy-
pothyroidism. The balance between stimulatory 
and blocking antibodies determines the level of 
thyroid function. Anti–thyrotropin-receptor anti-
bodies recognize epitopes on the alpha subunit. 
A recent study has shown the importance of the 
multimeric form of the alpha subunit in promot-
ing affinity maturation of these immunoglobu-
lins.27 Besides thyrotropin-receptor antibodies, 
antibodies directed at thyroglobulin and thyro-
peroxidase are frequently detected in patients with 
Graves’ disease. These antibodies most likely 
arise from antigen spreading and have no known 
pathological role. Activating antibodies target-
ing the insulin-like growth factor 1 receptor 
have also been detected in patients with Graves’ 
disease and may play a role in ophthalmopathy 
(discussed below).28
T Cells and B Cells
Both T cells and B cells, critical components of 
adaptive immunity, are necessary for the devel-
opment of Graves’ disease. Thymic education of 
immune cells leads to the deletion of autoreac-
tive T cells from the lymphocyte pool. These T cells 
show proliferative responses through antigen-
specific interactions occurring between T-cell 
receptors and major-histocompatibility-complex 
(MHC) molecules on antigen-presenting cells 
such as dendritic cells, monocytes, and B cells. 
T cells rely on second signals, without which 
they become anergic. Some T cells differentiate 
into effector-cell phenotypes that have the func-
tions of type 1, type 2, or type 17 helper T cells 
(Th1, Th2, or Th17). Others develop into regula-
tory T cells (e.g., regulatory T cells with the 
CD25+Foxp3+ phenotype), which can attenuate 
immune reactivity.29 Each phenotype produces a 
characteristic pattern of cytokines. The balance 
between proinflammatory factors and factors 
that dampen immune reactivity determines the 
amplitude and duration of immune responses. 
In Graves’ disease, autoreactive T cells against 
the thyrotropin receptor have escaped both cen-
tral (thymic) and peripheral editing. Receptors 
on these CD4+ helper T cells interact with MHC 
class II molecules through which thyrotropin-
receptor peptides are presented. Intrathyroidal 
T cells are particularly reactive to thyroid anti-
gens and predominantly have the Th2 pheno-
type.29 However, the issue of whether Graves’ 
disease is biased to the Th1 or Th2 functional 
subset remains controversial.30 Variable-region 
gene use by clonally expanded intrathyroidal 
T cells is biased as compared with peripheral-
blood T cells.31
B cells develop into antibody-producing plas-
ma cells in a process requiring second signals. 
The first of these signals is provided by antigen 
binding to the B-cell receptor and the second by 
CD40 on the B-cell surface interacting with 
CD40 ligand on T cells. These interactions result 
in the production of critical cytokines, such as 
interleukin-4, which promote antibody secretion 
and T-cell support of class switching. B cells ini-
tially produce IgM, which can be class-switched 
to IgG or IgE. Intrathyroidal B cells have re-
duced mitogenic responses but spontaneously 
secrete anti–thyrotropin-receptor antibodies. They 
are presumed to be the principal source for these 
antibodies, although peripheral-blood B cells are 
also a likely source.32
Thyroid Epithelial-Cell Involvement
The precise role (or roles) of thyroid epithelial 
cells in the pathogenesis of Graves’ disease re-
mains incompletely understood. These cells ex-
press important organ-specific antigens, such 
as the thyrotropin receptor, thyroglobulin, and 
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thyroperoxidase. Thyroid epithelial cells release 
several chemokines and thus may participate in 
the recruitment of these and other immune 
cells.33 In Graves’ disease, thyroid epithelial cells 
also express MHC class II molecules, probably as a 
consequence of infiltrating, lymphocyte-produced 
interferon-γ action in situ.34 Thus, although thy-
roid epithelial cells are not considered profes-
sional antigen-presenting cells, they have the 
potential to present thyroid antigens to T cells. 
In addition, their CD40 expression35,36 suggests 
the potential for direct, productive interactions 
between thyroid epithelium and antigen-specific 
T cells in Graves’ disease. The aggregate of cur-
A   Theoretical Model of Intrathyroidal Graves’ Disease
B   Theoretical Model of the Pathogenesis of Thyroid-Associated Ophthalmopathy
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rent information suggests that the epithelium 
plays a secondary, passive role in the pathogen-
esis of Graves’ disease after immune cells have 
infiltrated the thyroid gland.
Extrathyroidal Manifestations
In Graves’ disease, the immune pathogenesis of 
ophthalmopathy and that of hyperthyroidism 
are presumed to be similar. The orbital process 
primarily targets fibroblasts (Fig. 2B). During 
active disease, orbital tissues are variably infil-
trated with lymphocytes; their phenotypes and 
variable-region gene use have been partially 
characterized.37 Interactions between T cells and 
fibroblasts result in tissue activation and induc-
tion of genes involved in inflammation and tis-
sue remodeling.38 These events are mediated by 
several cytokines, including interleukin-1β, inter-
leukin-6, and CD40 ligand. Orbital fat and extra-
ocular muscles expand from accumulating hy-
aluronidase-digestible material and adipogenesis.12 
Extraocular muscles remain intact, but fibers be-
come widely separated. In later stages of the dis-
ease, extraocular muscles can become fibrotic, 
resulting in restricted motility. It remains uncer-
tain what provokes lymphocyte infiltration, but 
a shared antigen in the orbit and thyroid gland, 
such as the thyrotropin receptor, seems likely.12 
This view is supported by the relatively low level 
of expression in orbital fat and orbital fibro-
blasts.12,39,40 Fibroblasts inhabiting the orbit in 
Graves’ disease are heterogeneous, and when 
activated by cytokines, they produce hyaluronan 
and several inflammatory mediators. Fibroblasts 
that display CD34, CXCR4, and collagen 1 are ap-
parently derived from circulating fibrocytes,40,41 
which are monocyte-lineage progenitor cells with 
inflammatory characteristics. The unique pres-
ence of fibrocytes in the orbit in ophthalmopa-
thy suggests that they play a part in disease de-
velopment. Fibrocytes promiscuously express 
proteins previously thought to be restricted to 
the thyroid. These include thyrotropin receptor, 
thyroglobulin, thyroperoxidase, and sodium–
iodide symporter, the expression of which is 
driven by the autoimmune regulator protein.41,42 
Moreover, fibrocytes efficiently present antigens 
to T cells. When activated by thyrotropin or 
thyroid-stimulating immunoglobulins, fibrocytes 
release cytokines that have been implicated in 
Graves’ disease. Fibrocytes can differentiate into 
adipocytes or myofibroblasts and thus might 
contribute to the tissue remodeling in ophthal-
mopathy.
Involvement of the insulin-like growth factor 1 
receptor in ophthalmopathy is suggested by its 
overexpression by orbital fibroblasts, T cells, and 
B cells in Graves’ disease.28,43,44 Furthermore, 
serum antibodies against this receptor can be 
detected in some persons with the disease, al-
though the interpretation of this finding remains 
controversial. A functional and physical relation-
ship between the insulin-like growth factor 1 re-
ceptor and the thyrotropin receptor has been 
Figure 2 (facing page). Pathogenesis of Graves’ Disease 
Affecting the Thyroid Gland and Orbit.
Panel A shows a theoretical model of the pathogenesis 
of intrathyroidal Graves’ disease. Thyroid-stimulating 
immunoglobulins provoke the overproduction of thy-
roid hormones by activating the thyrotropin receptor, 
thus abrogating the normal regulatory role of thyro-
tropin. In addition, infiltrating immune cells such as  
B and T cells and antigen-presenting cells produce in-
terleukins 1β, 6, and 12; interferon-γ; tumor necrosis 
factor α; CD40 ligand; and other cytokines. These cyto-
kines, in turn, activate and sustain inflammation and 
alter the behavior of thyroid epithelial cells. Antithyroid 
drugs can attenuate the production of thyroid hormones 
and the expression of intrathyroidal cytokines and thus 
modulate the autoimmune process. Panel B shows a 
theoretical model of the pathogenesis of thyroid-asso-
ciated ophthalmopathy. The orbit becomes infiltrated by 
B and T cells and CD34+ fibrocytes. The bone marrow–
derived fibrocytes differentiate into CD34+ fibroblasts, 
which can further differentiate into myofibroblasts or 
adipocytes. CD34+ fibroblasts coinhabit the orbit with 
residential CD34− fibroblasts. These cells can all pro-
duce cytokines, depending on the molecular signals 
they encounter in the microenvironment. These include 
interleukins 1β, 6, 8, and 16; tumor necrosis factor α 
(TNF-α); RANTES (regulated on activation, normal T-cell 
expressed and secreted); and CD40 ligand. These cyto-
kines, in turn, activate orbital fibroblasts. The CD34+ 
fibroblasts express low levels of thyrotropin receptor, 
thyroglobulin, and other thyroid antigens. Thyroid-
stimulating immunoglobulins activate the thyrotropin–
insulin-like growth factor 1 (IGF-1) receptor complex, 
leading to the expression of inflammatory molecules 
and glycosaminoglycan synthesis. In addition, immuno-
globulins directed against the IGF-1 receptor can acti-
vate signaling in orbital fibroblasts, leading to cytokine 
and hyaluronan production. Cytokine-activated fibro-
blasts synthesize hyaluronan and other glycosamino-
glycans, which expand orbital tissue and cause propto-
sis and optic-nerve compression. In addition, the orbital 
fat expands, probably as a consequence of adipogene-
sis. MHC denotes major histocompatibility complex, 
and TGF-β transforming growth factor β.
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identified.45 Interrupting the insulin-like growth 
factor 1 receptor attenuates signaling down-
stream from the thyrotropin receptor,45 an obser-
vation that has subsequently been confirmed.46
Mechanisms involved in pretibial myxedema 
are even less well understood. The lesions are 
infiltrated with hyaluronan and are typically not 
inflammatory.
Di agnosis
Graves’ Hyperthyroidism
The diagnosis of hyperthyroidism is based on 
characteristic clinical features and biochemical 
abnormalities. Figure 3 shows a commonly used 
diagnostic algorithm, which is a sufficient tool 
for most cases. If pathognomonic features such 
Figure 3. Algorithm for Investigating the Clinical Suspicion of Graves’ Disease.
Not all experts rely on measurement of free thyroid hormone levels to determine the presence or absence of Graves’ disease. Some favor 
measurement of total thyroid hormone levels corrected for serum protein binding. At diagnosis, many favor measurement of both free 
thyroxine and free (or total) triiodothyronine levels. HCG denotes human chorionic gonadotropin.
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as ophthalmopathy or dermopathy are absent 
and a diffuse goiter is not detected, radionuclide 
scanning can confirm the diagnosis. These 
scanning studies and radioiodine uptake mea-
surement can be used to distinguish Graves’ 
disease from other causes of thyrotoxicosis. 
Routine measurement of thyrotropin-receptor 
antibodies is not mandatory, but when such as-
says are performed, they have 99% sensitivity and 
specificity for Graves’ disease.47 They are also 
helpful in diagnosing Graves’ disease in patients 
with concomitant nodular goiter.17 Assays that can 
routinely distinguish anti–thyrotropin-receptor 
antibodies that stimulate thyroid hormone pro-
duction from those that block thyroid hormone 
production are under development.48
Thyroid-Associated Ophthalmopathy
Computed tomography or magnetic resonance 
imaging of the orbit is warranted when the cause 
of ocular manifestations remains uncertain. 
These imaging studies are useful in distinguish-
ing extraocular muscle enlargement from fat 
expansion. Especially in cases of asymmetric 
proptosis, ruling out orbital tumor and arterio-
venous malformation is important. Assessment 
of the activity and severity of ophthalmopathy, 
which can usually be accomplished by clinical 
examination, helps guide therapy.49 Several other 
imaging techniques, including orbital ultraso-
nography, scintigraphy with radiolabeled octreo-
tide, gallium scanning, and thermal imaging, 
may be useful in more precisely defining the 
orbital disease.50
Ther a py
Hyperthyroidism
The discussion of treatment is limited to adult 
patients, since the management of Graves’ dis-
ease in the young warrants separate consider-
ation. Spontaneous remission occurs in a small 
proportion of patients with Graves’ disease, 
although data on patients with durable remission 
are unavailable. For patients who currently smoke 
or formerly smoked tobacco, the efficacy of 
medical therapy is reduced,51 and the importance 
of smoking cessation cannot be overstated. Auto-
immune hypothyroidism develops in 10 to 20% 
of patients during long-term follow-up. In un-
complicated cases, antithyroid drugs remain the 
first-line treatment in Europe9,52 and are increas-
ingly favored over radioiodine in North America.9 
Ablative therapy resulting in hypothyroidism, ei-
ther from radioactive iodine or surgical thyroidec-
tomy, necessitates lifelong thyroid hormone re-
placement. Thus, each treatment approach has 
advantages and drawbacks. The patient’s prefer-
ence, after receiving adequate counseling, remains 
a critical factor in therapy decisions. According to 
a randomized study with 14 to 21 years of follow-
up, quality of life was similar among the various 
treatment options, as was cost.53 Treatments for 
Graves’ hyperthyroidism and ophthalmopathy 
have been reviewed in detail previously.14,54,55 The 
most salient information is summarized in Ta-
bles 2 and 3.
Antithyroid Drugs
Methimazole, carbimazole (which is converted to 
methimazole and is not available in the United 
States), and propylthiouracil inhibit thyroid per-
oxidase and thus block thyroid hormone synthesis 
(Table 2). Propylthiouracil also blocks extrathy-
roidal deiodination of thyroxine to triiodothyro-
nine. Methimazole is preferred for initial ther-
apy in both Europe and North America because 
of its favorable side-effect profile.9,52 Both meth-
i m azole and propylthiouracil are associated with 
a high risk of recurrence after treatment has been 
withdrawn. Several variables appear to be asso-
ciated with durable disease remission, defined as 
biochemical euthyroidism for at least 12 months, 
after 1 to 2 years of therapy (Table 2). Durable 
remission occurs in 40 to 50% of patients. Re-
peated therapy carries an even lower likelihood 
of success. It remains uncertain whether remis-
sion results from immunomodulation by these 
drugs. The recurrence rate is not further de-
creased by providing treatment for more than 18 
months or by combining antithyroid drugs with 
levothyroxine. Patients may be switched from 
one drug to another when necessitated by minor 
side effects, but 30 to 50% of patients have a 
similar reaction to each drug.55 In our opinion, 
patients with severe side effects should not be 
further exposed to either drug. Monitoring by 
means of liver-function tests and white-cell counts 
before and during antithyroid drug therapy is 
advocated by some experts but is not currently 
supported by consensus opinion.8,9,55 One ran-
domized study showed no benefit from granulo-
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cyte colony-stimulating factor in patients with 
agranulocytosis.64
Radioactive Iodine
Radioactive iodine therapy has been used widely 
in patients with Graves’ disease for seven de-
cades.65 It offers relief from symptoms of hyper-
thyroidism within weeks. Treatment with anti-
thyroid drugs may be suspended 3 to 7 days 
before and after radiotherapy in order to enhance 
its efficacy, although this interval remains con-
troversial.66 Many clinicians use fixed doses of 
radioiodine, since calculation of activity is costly 
and fails to reduce rates of hypothyroidism or 
recurrent hyperthyroidism.65 Radioiodine is not 
associated with an increased risk of cancer67 but 
is known to provoke or worsen ophthalmopathy.14 
Instead, increased morbidity and mortality as-
sociated with Graves’ disease appear to be related 
to hyperthyroidism itself.4-7 Postablation thyroid 
function should be monitored throughout life, 
and if hypothyroidism develops, it should be 
treated immediately.
Surgery
Before patients undergo surgical thyroidectomy, 
their thyroid hormone levels should be normal 
to minimize the risk of complications or a poor 
outcome, which is higher for total thyroidectomy 
than for subtotal thyroidectomy. The risks of 
hypothyroidism and recurrent hyperthyroidism 
are inversely related and depend on the volume 
of residual tissue.68,69 Treatment with inorganic 
iodide commencing 1 week before surgery may 
decrease thyroid blood flow, vascularity, and 
blood loss but does not otherwise influence sur-
gical risk.70 Surgery may be an attractive option 
for patients with large goiters, women wishing 
to become pregnant shortly after treatment, and 
patients who want to avoid exposure to antithy-
roid drugs or radioiodine. It is recommended that 
women who have undergone surgery wait until 
the serum thyrotropin level stabilizes with levo-
thyroxine therapy before attempting conception. 
The course of ophthalmopathy appears to be 
unaffected by surgical thyroidectomy.8,20,71
Treatment during Pregnancy
Graves’ disease affects approximately 0.1% of 
pregnancies and carries a substantial risk of ad-
verse effects in mother and child, especially if 
it is inadequately treated.72 The lowest effective 
dose of an antithyroid drug should be used to 
maintain thyroid function at the upper limit of 
the normal range in order to avoid fetal hypo-
thyroidism. Both propylthiouracil and methima-
zole are associated with birth defects.57 The use 
of propylthiouracil in the first trimester and 
methimazole during the remainder of pregnancy 
is currently recommended on the basis of a con-
sideration of potentially severe birth defects.73 
Thyroid function should be monitored monthly. 
In up to 50% of cases, antithyroid drugs may be 
discontinued after the first trimester, but post-
partum relapse is common.72 If elevated by a fac-
tor of more than 3, the level of anti–thyrotropin-
receptor antibodies, beginning at a gestational 
age of 18 to 24 weeks, identifies pregnancies at 
risk for neonatal hyperthyroidism.72 Breast-feed-
ing is safe with either methimazole or propyl-
thiouracil, but methimazole is recommended for 
postpartum therapy and does not affect infant 
thyroid function in the doses commonly used.74,75
Ophthalmopathy
Treatment for ophthalmopathy depends on the 
phase and severity of the disease. The majority 
of patients require only conservative measures 
(Table 3). These include enhancement of tear-
film quality and maintenance of ocular surface 
moisture. Patients with disease that is severely 
symptomatic and sight-threatening may benefit 
from intravenously administered pulse glucocor-
ticoid therapy, which appears to have a more 
favorable side-effect profile than glucocorticoids 
administered orally, although pulse therapy is not 
without risks.60,61,76 Glucocorticoids are frequent-
ly effective in reducing inflammatory symptoms, 
but most experts do not believe that they modify 
the course of the disease. External-beam irradia-
tion of severely affected orbits is used in some 
specialized centers but not others.77 The combi-
nation of glucocorticoids and radiotherapy may 
provide a greater benefit than either treatment 
used alone.62 Orbital decompression surgery dur-
ing active disease is usually reserved for patients 
in whom compressive optic neuropathy has devel-
oped or is imminent.78 Decompression surgery is 
also indicated when the ocular surface is severely 
compromised. These situations constitute sur-
gical emergencies. Rituximab, a biologic agent 
that depletes CD20+ B cells, has been evaluat-
ed recently in two prospective, randomized pi-
lot studies involving patients with active, severe 
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ophthalmopathy. One trial suggested efficacy,79 
whereas the other did not.80
Therapy during the stable phase of moderate-
to-severe ophthalmopathy usually involves reha-
bilitative surgery aimed at reducing proptosis, 
restoring function, and enhancing appearance. 
The procedures are usually performed in a set 
sequence, beginning with orbital decompression. 
Multiple approaches to surgical decompression 
have been perfected, but controlled studies of their 
relative efficacies have not been performed.81 
The decision about which approach should be 
used depends on the primary objective of the 
surgery and the skill of the surgeon.78 In patients 
with diplopia, surgical decompression is followed 
by strabismus surgery to correct abnormalities 
of eye motility.82 Cosmetic and functional con-
cerns are addressed last, with facelifts, tissue 
fillers, and eyelid repair.
Most assessments of therapy for Graves’ hyper-
Therapy Mode of Action Pros and Cons Common Doses
Mild active disease
Topical solutions
Artificial tears Maintain tear film Rapid action, minimal side 
effects
Glucocorticoids Reduce inflammation Rapid action, minimal side 
effects
Avoidance of wind, light, dust, smoke Reduces ocular surface desic-
cation, reduces irritation
Elevation of head during sleep Reduces orbital congestion
Avoidance of eye cosmetics Reduces irritation Benefits not yet confirmed
Selenium59 Uncertain Benefits not yet confirmed
Moderate or severe active disease
Systemic glucocorticoids
Oral Reduce inflammation and 
orbital congestion
Hyperglycemia, hypertension, 
osteoporosis
Up to 100 mg of oral prednisone 
daily, followed by tapering of 
the dose60
Intravenous Reduce inflammation and 
orbital congestion
Rapid onset of anti-inflamma-
tory effect, fewer side effects 
than oral delivery, liver 
damage on rare occasions
Methylprednisolone, 500 mg/wk 
for 6 wk followed by 250 mg/wk 
for 6 wk61,62
Orbital irradiation Reduces inflammation Can induce retinopathy 2 Gy daily for 2 wk (20 Gy total)63
B-cell depletion* Reduces autoreactive B cells Very expensive; risks of infec-
tion, cancer, allergic re-
action
Two 1000-mg doses of intrave-
nous rituximab 2 wk apart
Emergency orbital decompression† Reduces orbital volume
Stable disease (inactive)
Orbital decompression (fat removal) Reduces orbital volume Postoperative diplopia, pain
Bony decompression of the lateral and 
medial walls
Reduces proptosis by enlarg-
ing orbital space
Postoperative diplopia, pain, 
sinus bleeding, cerebro- 
spinal fluid leak
Strabismus repair Improves eye alignment, 
reduces diplopia
Eyelid repair Improves appearance, 
reduces lagophthalmos, 
and improves function
*  B-cell depletion with the use of rituximab is currently considered an experimental treatment for ophthalmopathy; rituximab is not approved 
by the Food and Drug Administration for this indication.
†  Emergency orbital decompression is indicated for optic neuropathy or severe corneal exposure.
Table 3. Treatments for Thyroid-Associated Ophthalmopathy.
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thyroidism suggest that radioactive iodine abla-
tion increases the risk of new or worsening oph-
thalmopathy.8 Glucocorticoids appear to mitigate 
this risk.83 In contrast, most studies have failed 
to detect differences in the effect on ophthal-
mopathy between surgical thyroidectomy and 
medical therapy.
Dermopathy and Acropachy
Topical glucocorticoids can be used for symptom-
atic and extensive dermopathy but are usually in-
effective.21 The observation of a striking improve-
ment in dermopathy after rituximab infusion84 
suggests that B-cell depletion may benefit affect-
ed patients. However, this treatment is experi-
mental and has not been approved by the Food 
and Drug Administration. No specific therapy is 
available for acropachy.
Future Therapies
As we gain a clearer understanding of Graves’ 
disease, the potential for “smart drug” develop-
ment increases. Repurposing agents that effec-
tively disrupt cytokine networks in rheumatoid 
arthritis appears to be an attractive approach, but 
controlled, prospective trials are necessary. Agents 
blocking the thyrotropin and insulin-like growth 
factor receptors are under consideration.45,46 For 
example, a randomized, placebo-controlled clinical 
trial of the efficacy and safety of teprotumumab, 
an insulin-like growth factor 1 receptor–blocking 
monoclonal antibody, in patients with active, 
severe ophthalmopathy has recently been com-
pleted (ClinicalTrials.gov number, NCT01868997). 
Graves’ disease appears to be an ideal candidate 
for antigen-specific therapy, since the identity of 
a dominant self-antigen is known. Restoring im-
mune tolerance to the thyrotropin receptor and 
other relevant autoantigens remains the ultimate 
goal, sparing patients nonspecific immunosup-
pression and toxic drugs.
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